PMV Pharmaceuticals, Inc. — Q1 2021 Form 10-Q
Business context and reporting period. The unaudited quarter ended March 31, 2021. PMV is a clinical-stage precision oncology company developing small-molecule therapies targeting mutant p53; it has no approved products and has generated no revenue. Its lead candidate, PC14586, entered a Phase 1/2 trial in October 2020 and has FDA Fast Track designation for tumors with the p53 Y220C mutation.
Financial results and liquidity
- Revenue: None; the company does not expect product revenue in the foreseeable future.
- Expenses and loss: Operating expenses were $11.7 million, up $4.0 million from $7.7 million in Q1 2020. R&D was $7.5 million, up $1.5 million; G&A was $4.2 million, up $2.5 million. Net loss was $11.6 million versus $7.3 million; basic and diluted loss per share was $0.26 versus $2.38. The per-share comparison is affected by the substantially higher weighted-average share count following the 2020 IPO and preferred-stock conversion.
- Margins: Not meaningful because the company had no revenue.
- Cash flow: Operating cash use was $12.9 million, compared with $8.1 million in Q1 2020. Investing cash use was $139.9 million, primarily purchases of marketable securities; financing provided $0.2 million from option exercises. Cash and cash equivalents fell $152.6 million during the quarter, largely reflecting that investment activity.
- Liquidity: At March 31, cash and cash equivalents were $208.8 million and marketable securities were $139.6 million, for combined cash and securities of $348.4 million. Current assets were $335.0 million; accumulated deficit was $121.5 million.
- Debt and liabilities: No debt was reported. Total liabilities were $6.1 million, including $1.0 million in operating lease liabilities; stockholders’ equity was $348.3 million.
Changes versus the prior comparable period
- R&D expense rose about 26%, primarily due to increased discovery research costs and continued development of PC14586 in its Phase 1/2 trial.
- G&A expense rose about 146%, mainly from increased personnel and office costs, insurance, and outside services following the IPO and public-company buildout.
- Net loss widened by $4.3 million. Interest income declined to $0.1 million from $0.4 million.
- Cash used in operations increased by $4.8 million. The large investing outflow reflects purchases of securities; marketable securities were $139.6 million at quarter-end versus none at December 31, 2020.
Outlook, risks, and unusual items
- Management expects substantial additional operating losses and higher R&D spending as programs advance. It says cash, cash equivalents, and marketable securities at March 31 are expected to fund operations at least through 2023, while the liquidity note separately states the company believes it has funds for at least the next 12 months.
- The company may need additional equity, debt, collaboration, or other financing before generating product revenue. Financing may be unavailable or dilutive, and failure to obtain funding could force delays, reductions, or discontinuation of programs.
- In January 2021, PMV signed a lease for a planned 50,581-square-foot Princeton facility through 2032. Payments are expected to total $19.6 million through May 2032; the lease had not yet commenced and was not included in recognized lease liabilities at quarter-end.
- Key risks include clinical and regulatory failure or delay, uncertain development costs and timelines, competition, reliance on third-party research and manufacturing providers, intellectual-property protection, and possible COVID-19 disruption. The company reports no material litigation and no supplier purchase commitments at quarter-end.
- Management reported disclosure controls were effective as of March 31, 2021 and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether PC14586’s Phase 1/2 trial progresses on schedule and produces evidence of safety and efficacy.
- Whether the stated cash runway through 2023 remains supportable as clinical, staffing, and facility costs increase; note the different runway horizons stated in the filing.
- The timing, commencement, and full financial impact of the Princeton lease and facility buildout.
- Whether future funding needs lead to dilution, debt obligations, or partnering terms that affect the company’s programs or rights.
- How the increase in operating expenses translates into development progress, given that the filing does not allocate most R&D costs by candidate or program.